Apolipoprotein B (ApoB): The Better Cholesterol Number Most People Have Never Heard Of

Apolipoprotein B-100 is the structural protein that wraps around every LDL, VLDL, IDL, and Lp(a) particle. There is exactly one ApoB-100 per particle. So a serum ApoB measurement is a direct headcount of every atherogenic lipoprotein in circulation.

Why this matters: two people can have an identical LDL of 130 mg/dL, but one might carry that cholesterol on a smaller number of large, "fluffy" particles, and the other on a much larger number of small, dense particles. Same LDL, very different particle count. The second person — high ApoB, "discordant" with their LDL — has substantially more atherogenic particles bumping into their artery walls. Risk tracks particle count, not cholesterol mass.

The discordance is most common in people with insulin resistance, metabolic syndrome, type 2 diabetes, or high triglycerides. In those settings, the LDL number can be falsely reassuring while ApoB tells a different story.

Targets are risk-based, similar to LDL.

• Optimal (low risk, primary prevention): below 90 mg/dL.
• Moderate-to-high risk (diabetes, family history, metabolic syndrome): below 80 mg/dL.
• Established cardiovascular disease or very high risk: below 65 mg/dL, with some lipidologists pushing for under 60.

Above 130 mg/dL is high regardless of LDL. ApoB does not care about your LDL number. If you have 100 ApoB-bearing particles per deciliter, you have 100 ApoB-bearing particles per deciliter. The number on the LDL line is downstream.

Population data: the median ApoB in healthy adults is around 95–100 mg/dL. The median in people who have already had a heart attack is around 110–115 mg/dL. The 2026 ESC guidelines target ApoB below 65 in secondary prevention and below 80 in moderate-to-high primary prevention — these are the same people who would target LDL below 55 and 70, respectively.

An elevated ApoB means there are simply too many cholesterol-carrying particles available to deliver cholesterol into the artery wall. Whether the cholesterol cargo is high (high LDL) or low (low LDL but high particle count) does not change the mechanism — what matters is how often a particle is bumping into the endothelium.

Common drivers of high ApoB:

• Genetics, including familial hypercholesterolemia.
• Insulin resistance and metabolic syndrome. The classic "discordant ApoB" pattern — LDL looks moderate, ApoB is high, triglycerides are high, HDL is low.
• Diet high in saturated fat and refined carbohydrates.
• Hypothyroidism, kidney disease, nephrotic syndrome.
• Certain medications — corticosteroids, some atypical antipsychotics, retinoids.

How to lower ApoB:

• Statins — lower ApoB roughly proportionally to LDL: 30–50% on moderate intensity, 50%+ on high intensity.
• Ezetimibe — adds another 15–20% on top of a statin.
• PCSK9 inhibitors and bempedoic acid — drop ApoB further when statins alone are not enough.
• Diet — low-saturated-fat, plant-forward eating, soluble fiber.
• Weight loss and aerobic activity — modestly effective on their own, more powerful when combined.

The clinical evidence is the same as for LDL: probably not, in any range achievable with current medications. People with PCSK9 loss-of-function variants run lifelong ApoB in the 40s and have less heart disease and longer lifespans. Trials of PCSK9 inhibitors and bempedoic acid that drive ApoB into the 30s have not shown safety concerns.

Spontaneously low ApoB (below about 50 mg/dL in someone not on lipid-lowering therapy) is uncommon and worth investigating: hyperthyroidism, malabsorption, severe liver disease, hypobetalipoproteinemia, or active malignancy.

Most of the time ApoB and LDL track together — high LDL means high ApoB, low means low. But in a meaningful minority of patients, they disagree. That disagreement is called discordance, and it is where ApoB earns its keep.

• LDL ~ normal, ApoB high — usually insulin resistance with small-dense LDL particles. The patient looks "fine" on a standard panel but is at substantially higher cardiovascular risk than LDL would suggest. Treat to ApoB target.
• LDL high, ApoB ~ normal — usually large, "fluffy" LDL particles. Lower particle count, lower risk than LDL alone would suggest. Less aggressive treatment may be appropriate.

If your panel ever shows this kind of mismatch, ApoB wins for risk stratification. Several large studies (INTERHEART, AMORIS, MESA) have found ApoB outperforms LDL for predicting cardiovascular events when the two disagree.

How often to retest: with the same cadence as your LDL — every 6–12 months while titrating therapy, then annually once stable.

• ApoB above 130 mg/dL on any test — high regardless of LDL; treatment usually warranted.
• ApoB above 90–100 with diabetes, metabolic syndrome, or family history — above target for moderate-to-high risk; treatment typically indicated.
• "Normal" LDL but ApoB above 100 — discordance pattern; the LDL is misleading you. Treat to ApoB target.
• After a heart attack, stroke, or stent — target ApoB below 65, monitor every 3–6 months until stable.

• LDL Cholesterol — the cholesterol cargo on the same particles ApoB counts.
• Triglycerides — high triglycerides drive the discordance pattern.
• HDL Cholesterol — the trig/HDL ratio predicts whether your LDL and ApoB will agree.
• Lipoprotein(a) — independent particle, included in the ApoB count, but should be measured separately at least once in adulthood.
• hs-CRP — inflammation marker that complements particle count.